Managing accruals and contracts effectively remains one of the biggest challenges facing life sciences organizations today
Chicago, IL (PRWEB) July 20, 2008
ClearTrial (http://www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kristin Lucas, ClearTrial Senior Director of Clinical Services, will speak at the IIR Cost & Contract Management for Clinical Trials Conference, being held September 22-24 at the Sheraton University City Hotel in Philadelphia, Pennsylvania. Lucas will demonstrate how biopharmaceutical organizations are using Earned Value Analysis (EVA) to gain greater control over clinical trial accruals, payments, and contracts.
"Managing accruals and contracts effectively remains one of the biggest challenges facing life sciences organizations today," noted Michael Soenen, Managing Partner at ClearTrial. "Earned Value Analysis - used widely in other industries - is rapidly gaining favor as a powerful tool to gain advanced visibility and to maintain control over clinical development projects, whether in-house, outsourced, or a combination."
During her session, Lucas will explore the underpinnings of EVA and its direct applications for clinical development, and offer practical guidelines and case study examples for implementing Earned Value Analysis in a biopharmaceutical organization.
Attendees will discover how EVA can help them:
- Quickly determine if studies are on budget and on schedule
- Obtain a fast, accurate assessment of accruals based on actual work performed
- Generate precise accruals forecasts based on when work is actually performed
- Effectively track contract performance and timelines
Lucas brings more than 15 years of experience in the pharmaceutical and biotech industry to the conference, with extensive experience in clinical trial budgeting and contract management. Before joining ClearTrial, she led the Financial Administration division for the Clinical Business Management department at ICOS Corporation (an Eli Lilly company), where she worked on the blockbuster drug Cialis®. At ICOS, Lucas was responsible for establishing best practices in the outsourcing, management, drafting and negotiation of site and vendor agreements, as well as the development of a clinical budgeting/modeling application for lifecycle planning, budgeting and in-licensing opportunity assessment. In addition, she led the Sarbanes-Oxley audit preparedness project, resulting in ICOS achieving SOX compliance in 2006. Prior to ICOS, Lucas spent seven years with Genentech, where she was responsible for the negotiation, positioning, and pricing strategy for managed care contracts. She has extensive education and training in project management, negotiation, costing of clinical studies, advanced financial modeling, and marketing and business administration.
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.
ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.
# # #